Featured Stories

Preclinical Screening Model: Reversion of Neuropathic Pain In Vivo


We have established a comprehensive in vivo model for the assessment of neuropathic pain treatment options. This rat model of spinal nerve ligation (SNL)-induced neuropathy has been validated with several antinociceptive agents. With this data, we have demonstrated the model’s reliability for testing treatment effects.

Novel Kidney Biomarker Assays Now Available


With the emergence of sensitive novel kidney injury markers, we are excited to announce the availability of multiplexed assays to analyze these biomarkers in the urine of rats and large animals.  

Charles River France, Germany and Italy Receive AAALAC Accreditation


Charles River is proud to announce that its research model breeding and services facilities in France, Germany and Italy have recently received full accreditation of their animal care and use programs from AAALAC International. Only a handful of commercial breeders in Europe have received this prestigious accreditation.

Assessing Human Exposure Risks


The maximum risk of human exposure to any agrochemical product arises during manufacture, equipment preparation and application of the product. Regulatory requirements state that the exposure risk to the individual should be properly assessed at each point in the production, preparation and application process so that appropriate protective equipment, handling and exclusion procedures can be recommended.

Flow Cytometry Enhances Syngeneic Mouse Models in Oncology Drug Discovery


Immunocompetent syngeneic mouse tumor models serve as a surrogate for human patients and allow us to study how cancer therapies perform in conjunction with a functional immune system. Flow cytometry enables validation of a functional immune system and the ability to determine various cell populations. Evaluation of these cell populations then makes it possible to characterize an immune response elicited from novel therapeutics.

Displaying results 1-10 (of 152)
 |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >|